CytoSorbents Reports Second Quarter 2023 Financial and Operational Results
August 01, 2023 16:15 ET
|
CytoSorbents
Q2 2023 Total Revenue was $9.4 million, an 11% increase from $8.5 million in Q2 2022. Product sales rose 10% to $8.1 million vs $7.3 million in Q2 2022. Product gross margins grew 700 basis points...
CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial
July 07, 2023 07:07 ET
|
CytoSorbents
PRINCETON, N.J., July 07, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood...
CytoSorbents Announces Independent Data Safety and Monitoring Board Recommends Completion of the Pivotal STAR-T Trial Without Modifications Following Second Scheduled Safety Review
June 15, 2023 07:00 ET
|
CytoSorbents
PRINCETON, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents’ Pivotal STAR-T Trial Reaches Second Key Milestone With 80 Patients Enrolled
April 20, 2023 07:00 ET
|
CytoSorbents
PRINCETON, N.J., April 20, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
New European “Guidelines for the Management of Severe Perioperative Bleeding” Consider Hemoadsorption for the First-Time
March 07, 2023 07:00 ET
|
CytoSorbents
PRINCETON, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
Updated AHA/ACCF Guidelines for Unstable Angina Include Newest Blood Thinning Drug
July 16, 2012 14:00 ET
|
American Heart Association
Statement Highlights:
The blood-thinning drug ticagrelor is now considered equal to blood thinners clopidogrel and prasugrel for treating some patients who have a heart attack or chest...